Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ACST
- Price
- -
- Stock movement down
- -0.03 (-0.88%)
- Company name
- Acasti Pharma Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 34.17M
- Ent value
- 28.23M
- Price/Sales
- -
- Price/Book
- 0.61
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -46.19%
- 1 year return
- 42.19%
- 3 year return
- -30.60%
- 5 year return
- -48.56%
- 10 year return
- -36.14%
Last updated: 2024-12-16
DIVIDENDS
ACST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.61 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 10.14M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | -1.12 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 15.15M |
| Net receivables | 0.00 |
| Total current assets | 16.06M |
| Goodwill | 8.14M |
| Intangible assets | 41.13M |
| Property, plant and equipment | 21.00K |
| Total assets | 65.35M |
| Accounts payable | 1.68M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 2.67M |
| Total liabilities | 9.21M |
| Shareholder's equity | 56.13M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| ACST | S&P500 | |
| Current price drop from All-time high | -99.83% | -0.95% |
| Highest price drop | -99.91% | -19.00% |
| Date of highest drop | 22 Sep 2023 | 8 Apr 2025 |
| Avg drop from high | -87.05% | -2.76% |
| Avg time to new high | 87 days | 5 days |
| Max time to new high | 2817 days | 89 days |
COMPANY DETAILS
Marketcap
34.17M
Marketcap category
Small-cap
Description
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Janelle D'Alvise
Country
USA
City
Laval
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner